Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.
MillerCoors had contended that its rival used "false and misleading" advertising to imply its brews include a potentially fattening form of corn syrup.
Allergan announces it has reached a settlement with two plaintiffs in Ohio in the multi-district federal litigation over opioids.
No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.
Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.
I am not focused on today's price movement of the stock but the pattern from the end of 2017.
An Oklahoma judge is expected to issue what will be a landmark ruling Monday on whether Johnson & Johnson will be held responsible for the state's opioid epidemic that officials say led to more than 6,000 deaths over nearly two decades.
The news comes the same week that Tesla CEO Elon Musk announced a solar panel rental program that seemed designed to boost business at the division.
Understanding yourself and the investing environment you are in are keys to avoiding panic brought on by fear.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.